Cartesian Therapeutics, Inc. entered into securities purchase agreement for issuance of 149,330 shares of series A preferred stock at a price of $403.468 for an aggregate gross proceeds of $60.25 million on November 13, 2023. Each share of series A preferred stock is convertible into 1,000 shares of common stock. The transaction will include participation from lead investor Timothy A. Springer.